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Diffuse Myocardial Interstitial Fibrosis and
Dysfunction in Early Chronic Kidney Disease
Manvir Kaur Hayer, MB, ChBa,b,*, Anna Marie Price, MB, ChBa,b, Boyang Liu, MA, MBBSc,b,
Shanat Baig, MBBSc,b, Charles Joseph Ferro, PhDa,b, Jonathan Nicholas Townend, MDc,b,
Richard Paul Steeds, MA, MDc,b, and Nicola Catherine Edwards, PhDc,b
Patients with chronic kidney disease (CKD) have a disproportionately high risk of cardio-
vascular (CV) morbidity and mortality from the very early stages of CKD. This excess risk
is believed to be the result of myocardial disease commonly termed uremic cardiomyopa-
thy (UC). It has been suggested that interstitial myocardial fibrosis progresses with advancing
kidney disease and may be the key mediator of UC. This longitudinal study reports data
on the myocardial structure and function of 30 patients with CKD with no known
cardiovascular disease and healthy controls. All patients underwent cardiac magnetic
resonance imaging including T1 mapping and late gadolinium enhancement (if estimated
glomerular filtration rate > 30 ml/min/1.73 m2). Over a mean follow-up period of 2.7 ± 0.8
years, there was no change in left ventricular mass, volumes, ejection fraction, native myo-
cardial T1 times, or extracellular volume with CKD or in healthy controls. Global longitudinal
strain (20.6 ± 2.9 s−1 vs 19.8 ± 2.9 s−1, p = 0.03) and mitral annular planar systolic excur-
sion (13 ± 2 mm vs 12 ± 2 mm, p = 0.009) decreased in CKD but were clinically insignificant.
Midwall late gadolinium enhancement was present in 4 patients at baseline and was un-
changed at follow-up. Renal function was stable in this cohort over follow-up (change in
estimated glomerular filtration rate was −3 ml/min/1.73 m2) with no adverse clinical CV
events. In conclusion, this study demonstrates that in a cohort of patients with stable CKD,
left ventricular mass, native T1 times, and extracellular volume do not increase over a period
of 2.7 years. © 2017 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/). (Am J Cardiol
2018;121:656–660656656–660–660660)
The increased cardiovascular morbidity and mortality of
patients with chronic kidney disease (CKD) is due to a com-
bination of myocardial disease, arteriosclerosis, and
atherosclerosis.1,2 The ability of cardiovascular magnetic reso-
nance (CMR) imaging to characterize myocardial disease at
the same time as providing accurate and reproducible as-
sessment of left ventricular (LV) structure and function has
redefined ‘renal cardiomyopathy.’ The subendocardial and
midwall patterns of late gadolinium enhancement (LGE) in
end-stage kidney disease were first reported in 2005.3 More
recently, the emergence of T1 mapping techniques, without
contrast, has demonstrated increased myocardial T1 relax-
ation times indicative of diffuse interstitial fibrosis in end-
stage kidney disease.4,5 Similar though less severe changes
in T1 relaxation times and extracellular volume (ECV) ex-
pansion are also present in patients with early-stage CKD but
not essential hypertension.6 It has been postulated that
interstitial myocardial fibrosis is progressive with advanc-
ing CKD and that ‘uremic cardiomyopathy’ represents the end-
stage phenotype. To date, however, there have been no
longitudinal data to support this hypothesis. The aim of this
study was to report 2- to 3-year follow-up CMR data from
our cohort of patients with early-stage CKD and healthy con-
trols to provide information on the natural history of these
changes.
Methods
Patients who participated in an observational study inves-
tigating the use of CMR T1 mapping in early-stage CKD
during 2012 to 2014 were invited to participate in an ongoing
study examining myocardial disease and LV fibrosis in CKD
(NCT03176862).6 Inclusion criteria were as follows:
CKD stage 2 (estimated glomerular filtration rate [eGFR]
60 to 89 ml/min/1.73 m2 with other evidence of kidney disease:
proteinuria/hematuria/structural abnormality/genetic),
stage 3 (eGFR 30 to 59 ml/min/1.73 m2), stage 4 (15 to
29 ml/min/1.73 m2), and stage 5 (<15 ml/min/1.73 m2,
predialysis) with no history or symptoms of cardiovascular
(CV) disease or diabetes. Healthy controls and hypertensive
subjects in the original cohort were also invited to partici-
pate. The study was approved by the National Research Ethics
Service—East Midlands (15/EM/0280) and all subjects gave
written informed consent. Demographic, medical co-
morbidities, and blood and proteinuria data were collected
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prospectively. Glomerular filtration rate was assessed using
the CKD-EPI equation. CV events were defined as death from
CV disease, myocardial infarction, stroke, peripheral vascu-
lar disease, or hospital admission with heart failure.
All subjects underwent CMR (1.5 T Siemens Avanto, Er-
langen, Germany) with a phased array 18-channel body matrix
coil and spine matrix coil. Imaging sequences for LV and right
ventricular structure, function, and LV mass were acquired
in line with standard protocols.7 Vertical long-axis and hori-
zontal long-axis steady-state free precession cine images
(retrospective electrocardiographic gating) were used to pilot
the LV short-axis stack (SAX) acquired using serial cines
(typical parameters were resolution of 40 to 50 millisec-
onds, repetition time of 3.2 milliseconds, echo time of 1.7
milliseconds, flip angle of 60°, field of view of 300 mm, in-
plane resolution of 1.5 × 1.5 mm2, slice thickness of 7 mm
with 3 mm gap, minimum 25 phases per cardiac cycle). T1
mapping was performed before and 15 minutes after gado-
linium administration on the basal and mid-SAX slices in
diastole using an electrocardiography-gated Modified Look-
Locker Inversion recovery (MOLLI) sequence with a 3(3)5
sampling protocol (Siemens WIP 448). Typical acquisition
parameters were pixel bandwidth of 977 Hz/pixel; echo
time = 1.1 milliseconds; flip angle = 35°; matrix = 144 × 256;
slice thickness of 6 mm. Motion correction and a nonlinear
least-square curve fitting were performed with the set of images
acquired at different inversion times to generate a paramet-
ric pixel-wise color T1 map to quantitatively measure the
longitudinal myocardial relaxation time. LGE imaging was
acquired in the corresponding SAX stack and LAX views using
a standard inversion recovery sequence 7 to 10 minutes after
0.15 mmol/kg of gadolinium contrast bolus (Gadovist Bayer
Health Care, Newbury, Berkshire, England). For the origi-
nal study, ethical approval allowed administration of
gadolinium to subjects with eGFR > 15 ml/min/1.73 m2.
This dose was amended in the follow-up study to
eGFR > 30 ml/min/1.73 m2 because of local policy change and
guidance from the Medicines and Healthcare Products Regu-
latory Agency.
Offline analysis was performed by experienced opera-
tors (MK, NE) using CVi 42 software (version 5.3.4 cvi42,
Circle Vascular Imaging, Calgary, Canada). Analysis of LV
function, volume, and LV mass was performed with delin-
eation of papillary muscles and trabeculations using
thresholding. Tissue tracking in the 3 long-axis views was per-
formed offline to assess 2-dimensional global longitudinal
strain (GLS), strain rate, and early diastolic strain rate. Native
and postcontrast myocardial T1 values were measured from
parametric T1 maps. Endocardial and epicardial borders were
manually drawn in the basal and mid short-axis slices with
meticulous care to avoid partial voluming and blood pool con-
tamination. Anterior and inferior septal borders were defined
with semiautomated segmentalization of the LV in accor-
dance with the AHA model.8 Average anteroseptal and
inferoseptal T1 times were reported. ECV was calculated using
validated formulas as previously described.6 Areas contain-
ing LGE, consistent with previously undiagnosed infarction
or right ventricular insertion point LGE, were excluded from
the T1 and ECV analysis.9
All T1 map studies were analyzed twice by a single blinded
observer (MKH) for intraoperator reproducibility and a second
blinded observer (AP) for interoperator reproducibility. Analy-
sis was performed on studies anonymized to time and date
by a third observer who assigned a unique number to all scans
before analysis.
Continuous variables are expressed as mean ± SD if nor-
mally distributed or median (25th to 75th percentile) if non-
normally distributed. Paired group comparisons for continuous
data were made using the paired samples t test or the Wilcoxon
signed-rank test for parametric and nonparametric data, re-
spectively. Paired nominal data were compared using the
McNemar test. Statistical tests were 2-tailed, and a p
value <0.05 was considered to indicate statistical significance.
Results
In total, 30 subjects with CKD from the original cohort
(43 subjects) were followed up for a mean period of 2.7 ± 0.8
years. Baseline and follow-up demographic, biochemical, and
treatment data for the patients with CKD are presented in
Table 1. The mean age at baseline was 57 ± 10 years, and 60%
of the participants studied were male. There was no differ-
ence between patients who returned for follow-up and those
who did not (data not shown). The etiologies for CKD in the
study cohort were as follows: primary glomerulopathy (37%),
polycystic kidney disease (30%), vasculitis (13%), hypertension
Table 1
Demographic, biochemical, and treatment data
Variable CKD Patients (n = 30) p Value
Baseline Follow Up
Body surface area (m2) 1.87 ± 0.17 1.89 ± 0.15 0.21
Body mass index (kg/m2) 27 ± 5 27 ± 3 0.66
Hemoglobin (g/L) 126 ± 17 133 ± 15 0.01
Hematocrit (%) 0.37 ± 0.05 0.39 ± 0.04 0.10
Serum creatinine (mg/dL) 1.71 ± 1.02 1.96 ± 1.75 0.03
N-terminal pro B Natriuretic
peptide (ng/L)
81 (38–169) 85 (32–220) 0.29
Total cholesterol (mg/dL) 178 ± 39 193 ± 50 0.25
Estimated glomerular filtration
rate (ml/min/1.73 m2)
53 ± 23 50 ± 23 0.02
CKD stage, n 0.03
1 2 (7%) 1 (3%)
2 12 (40%) 11 (37%)
3 10 (33%) 11 (37%)
4 5 (17%) 4 (13%)
5 1 (3%) 3 (10%)
Urine albumin to creatinine ratio
(mg/g)
51 (19–242) 70 (18–158) 0.72
Office systolic blood pressure
(mmHg)
129 ± 12 132 ± 17 0.48
Office diastolic blood pressure
(mmHg)





25 (83%) 26 (87%) 0.25
Diuretic 7 (23%) 6 (20%) 0.38
Beta blocker 2 (7%) 3 (10%) 0.38
Calcium channel blocker 8 (27%) 9 (30%) 0.38
Statin 8 (27%) 12 (40%) 0.44
Data are frequency (%), mean ± SD, or median (interquartile range).
657Miscellaneous/Myocardial Interstitial Fibrosis and Dysfunction in CKD
(7%), and others (13%). No patients experienced a CV event
during follow-up. Using the National Institute for Health and
Care Excellence (NICE) guidance, no patients had progres-
sive CKD as defined by a sustained decrease in eGFR ≥ 25%/
year or ≥15 ml/min/1.73 m2/year over the study period [median
and interquartile range for change in eGFR −2 (−10.5 to 1.75)]
but 7 patients did change their CKD category during the
follow-up period.10 Eight healthy volunteers from the origi-
nal cohort (43 subjects) agreed to be re-studied. There was
no change in systolic blood pressure in the CKD or control
groups, but diastolic blood pressure did increase in patients
with CKD (Table 1).
Cardiac magnetic resonance imaging data for patients with
CKD are presented in Table 2. There was no change in LV
volumes, mass, or systolic function assessed using ejection
fraction for the CKD or the control groups. A small reduc-
tion in mitral annular planar systolic excursion and GLS was
observed, although values remained within the normal range
(Figure 1). There was no change in myocardial T1 times
(Figure 2) or ECV in either group. Because of changes in
ethical approval, gadolinium was only administered to pa-
tients with eGFR > 30 ml/min/1.73 m2 (22 of 30 subjects) at
follow-up. Midwall LGE was observed in 4 patients. None
had subendocardial LGE. There were no new cases of myo-
cardial LGE in either CKD or control groups over follow-up,
but 4 patients with CKD did develop new focal right ven-
tricular insertion point LGE (Table 2).
In subgroup analyses in the 4 patients with myocardial LGE
at baseline, there was no increase in myocardial T1 times,
or reduction in GLS and peak systolic strain rate at follow-
up (data not shown). In those patients from the original study
with native myocardial T1 values greater than the upper limit
observed in controls (8 patients, T1 > 985 milliseconds), there
was no change in myocardial T1, ECV, LV function, or LV
mass. There was no systemic bias detected by Bland-
Altman analysis between intra- and interoperator agreement
for native myocardial T1 times. The mean intra- and
interobserver differences [mean ± SD (95% limits of agree-
ment)] were −1 ± 6 (−12 to 10) and −1 ± 7 (−13 to 11),
respectively.
Discussion
This study demonstrates that in a cohort of patients with
predominantly stable CKD, with controlled blood pressure
and without known CV disease or diabetes, myocardial T1
times and ECV do not change over 2.7 years. There is also
stability of LV ejection fraction and LV mass. These data are
encouraging in that they demonstrate stability in the CMR
measurement of T1 relativity in the context of CKD. The data
are also reassuring for patients with stable early CKD and
provide further support for remote community follow-up of
such patients provided that blood pressure and renal func-
tion are monitored.
This is the first longitudinal study evaluating T1 and ECV
in early CKD. No progression of T1 times or ECV was found
in subjects over 2.7 years. We cannot exclude progression of
these parameters over longer time periods and we are not able
to comment on the influence of declining renal function. In
keeping with these findings, a recent small longitudinal study
of 22 hemodialysis (HD) patients studied twice over 6 months
did not show a change either in septal T1 times or in BNP.11
LV mass in this study fell with the introduction of HD, which
may imply a greater regression of myocyte hypertrophy rather
than change in the extracellular environment including fi-
brosis, as has been reported using ECV assessment after aortic
valve replacement.12
The unexpected stability of CKD in the study prevents us
from addressing our original hypothesis that deteriorating renal
function promotes myocardial fibrosis, a key intermediary in
the progression of UC. It should be noted that this is not a
new concept, as the earliest reports of histology dating back
to the late 1980s from postmortem and cardiac biopsies con-
firmed that extensive fibrosis is detected in HD patients.13 It
is interesting that 3 groups who have published using T1
mapping in CKD have looked at different stages of disease
(early stage 2 to 4, dialysis with short vintage 5.5 months and
longer vintage 21 months). Although it is not possible to
compare absolute T1 values directly because of different se-
quences and magnet strengths (native values being higher at
3 T), it does appear that any difference in T1 between con-
trols and patients increases with severity of disease and dialysis
vintage. Edwards et al reported higher native septal T1 times
and ECV, with 14% showing evidence of irreversible fibrosis
Table 2






Left ventricular ejection fraction (%) 69 ± 9 71 ± 6 0.14
Left ventricular end diastolic volume
index (ml/m2)
67 ± 15 67 ± 11 0.92
Left ventricular end systolic volume
index (ml/m2)
20 ± 8 22 ± 13 0.52
Left ventricular mass indexed (g/m2) 62 ± 14 62 ± 11 0.71
Native septal T1 time (ms) 967 ± 27 970 ± 26 0.19
Septal extracellular volume (%)* 26.1 ± 2.2 26.6 ± 1.7 0.33
Post contrast septal T1 time (ms)* 437 ± 37 448 ± 26 0.13
Presence of late gadolinium
enhancement, n*
Right ventricular insertion point 4 (13%) 8 (36%) 0.05
Mid wall/diffuse 4 (13%) 4 (18%) -
Native T1 times in areas of right
ventricular insertion point
LGE (ms)
1043 ± 35 1063 ± 32 0.15
Native T1 time in areas of mid wall
late gadolinium enhancement (ms)
1028 ± 40 1050 ± 51 0.55
Mitral annular planar systolic
excursion (mm)
13 ± 2 12 ± 2 0.01
Global longitudinal strain (%) 20.6 ± 2.9 19.8 ± 2.9 0.03
Global longitudinal systolic strain
rate (s−1)
1.12 ± 0.17 1.07 ± 0.22 0.26
Global longitudinal early diastolic
strain rate (s−1)
0.92 ± 0.24 0.89 ± 0.26 0.57
Data are frequency (%) or mean ± SD. Values are indexed for body
surface area.
Myocardial T1 times were assessed in the left ventricular septum from
the basal and midventricular levels and averaged to yield the “septal T1 time.”
Measurements excluded myocardial and right ventricular insertion point late
gadolinium enhancement.
* Eight patients did not receive gadolinium contrast in the follow-up
cardiovascular magnetic resonance study as eGFR had fallen to
<30 ml/min/1.73 m2.
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by LGE in patients in stage 2 to 4 CKD. The authors ac-
knowledged a degree of overlap of T1 times with controls
as has been reported with other disease entities.6 Rutherford
et al showed higher septal and global T1 times, as well as a
correlation with LV mass in HD patients with a short vintage
compared with healthy volunteers but again an overlap of T1
times.5 However, data from a HD cohort with a long vintage
showed native septal T1 times were all above the T1 times
seen in healthy controls in support of progressive and more
extensive fibrosis. Furthermore, 50% of HD patients had dis-
crete midwall T1 signal comparable with that seen with LGE
in DCM.4 Our data demonstrated myocardial LGE in only 4
subjects (13%) at baseline and follow-up but a significant in-
crease in right ventricular insertion point LGE. The significance
of this pattern of LGE is not fully understood, although it
appears that the pattern has a lower risk profile than myocardial
LGE in other disease cohorts.14 Autopsy examination has
shown increased collagen and fat between fiber bundles (plexi-
form fibrosis), which is consistent with myocardial disarray
but not pathologic fibrosis.15 It is clear that cross-sectional
studies to date are, however, not definitive and these and our
present study highlight the need for a large-scale, longitudi-
nal follow-up study of patients with progressive CKD, for
example, in those with high proteinuria, uncontrolled blood
pressure, diabetes, and varying socioeconomic class.
GLS provides a potential functional biomarker for CKD
cardiomyopathy. It provides a quantitative evaluation of ven-
tricular global and regional function that has been linked to
Figure 1. Change in global longitudinal strain between baseline and follow-up. The vertical line in each box represents the median, the boxes represent the
25th to 75th percentile, and the whiskers represent the minimum and maximum values in each dataset.
Figure 2. Change in native myocardial septal T1 times between baseline and follow-up. The vertical line in each box represents the median, the boxes rep-
resent the 25th to 75th percentile, and the whiskers represent the minimum and maximum values in each dataset.
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the extent of myocardial fibrosis and is a better predictor of
mortality and adverse CV events in a range of conditions
particularly when EF is within normal range.16–19 We showed
a very small reduction in GLS over time in the absence of a
change in LV mass, systolic blood pressure, or BNP, but ac-
knowledged that the values remain within the normal range
and this finding is of questionable significance in this small
cohort. Nevertheless, the statistically significant result seen
with GLS raises the question whether strain may be a more
sensitive imaging biomarker than native myocardial T1 times.
Serum biomarkers of fibrosis also appear to be important in
detecting and monitoring myocardial disease in CKD, with
recent data confirming a trend with galectin-3 and GLS in
HD patients.5
There are several limitations to acknowledge; the effects
of progressive renal dysfunction on myocardial disease cannot
be addressed from this study because of the stability of our
patient’s CKD. Our patients with mainly low levels of pro-
teinuria, no diabetes, and well-controlled blood pressure were
a relatively low-risk cohort and we note that other studies have
reported considerable variability in rates of renal progres-
sion over such a time period.20 This is a small study and it
is not possible to exclude selection bias in the 30 patients who
returned for follow-up. However, the other 13 patients from
the original study were all contacted and confirmed to be well
and without reported progression to renal replacement therapy
or CV events.
In conclusion, in patients with early-stage CKD, nonin-
vasive imaging biomarkers of myocardial fibrosis do not
progress if renal function remains stable. These findings are
paralleled by stability of LV mass and systolic function.
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